We have a License Agreement with Allogene Therapeutics, Inc., according to which we granted to Allogene an exclusive, worldwide license to develop and commercialize CAR T-cell products directed at a total of 15 selected targets, including BCMA, FLT3, DLL3 and CD70, for human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes.
Financials:
Up to $2.8B In Development & Sales Milestones + High Single-Digit Royalties on Sales
We have a License, Development and Commercialization Agreement with Les Laboratoires Servier, according to which Servier has an exclusive worldwide license to develop and commercialize gene-edited allogeneic CAR T-cell products targeting CD19, including ALLO-501 and ALLO-501A. The exclusive rights for the development and commercialization of such products in the United States have been sublicensed by Servier to Allogene (such rights having been previously held by Pfizer, Inc. and transferred to Allogene).
In September 2022, Servier communicated that it was discontinuing its involvement in the development of in-licensed CD19 products and purporting to provide Allogene with the ability to elect to obtain a license to the CD19 Products outside of the United States. We are evaluating all available options and contractual remedies to address the foregoing matters and other performance issues, which we believe may involve material breaches of the Servier Agreement by Servier.
Financials:
Up to $410M In Development & Sales Milestones + Low Double-Digit Royalties on Sales
We have a research collaboration and exclusive worldwide license agreement with Iovance Biotherapeutics, Inc. enabling Iovance to use certain TALEN® technology addressing multiple gene targets to modify tumor-infiltrating lymphocytes (TIL) for therapeutic use in several cancer indications.
Financials:
Undisclosed
We have a collaboration agreement with Primera Therapeutics, Inc., under which Primera together with Cellectis is co-developing an engineering toolbox to edit mutations in the mitochondrial DNA (mtDNA) in vivo to treat the root causes of mitochondrial diseases. Primera has a right to exercise an exclusive worldwide option for a license from Cellectis on up to five product candidates developed under the collaboration.
Financials:
Option for up to $750M in Development & Sales Milestones + High Single-Digit Royalties on Sales
Cell & Gene Therapy R&D Collaboration:
Investment Agreement:
Note: Immediately following the Additional Investment, it is anticipated that AstraZeneca would own approximately 44% of the share capital of Cellectis and 30% of the voting rights of Cellectis (based on the number of voting rights outstanding immediately after the completion of the Initial Investment) and would have the right to nominate two directors to the board of directors of Cellectis. Further, certain business decisions are subject to AstraZeneca’s approval.